09966.HK
Alphamab Oncology
HKSE · Healthcare · Biotechnology · CN
HKD 6.49
−0.92%Margins
Gross margin
76.1%
EBITDA margin
-25.4%
EBIT margin
-38.0%
Net margin
-33.8%
FCF margin
-33.4%
-10.4%
Return on equity
-8.0%
Return on assets
-10.1%
Return on invested capital
0.24x
Asset turnover
-HKD 183.3M
Cash from operations
HKD 1.75
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026